徐再靜蕭旻樺Min-Hua Hsiao生化微生物免疫研究所2026-10-299999-12-312019https://handle.ncl.edu.tw/11296/cswe4bhttps://scholars.csmu.edu.tw/handle/123456789/36452肝細胞癌 (Hepatocellular carcinoma, HCC) 在全球癌症死亡率排行第四。在台灣，感染B型肝炎及C型肝炎是引起肝癌的主要原因，研究顯示B型肝炎帶原者可以在持續服用抗病毒藥物治療下，達到延緩肝病進展及預防或降低肝硬化、肝衰竭甚至肝細胞癌的發生。先前有研究指出抗病毒藥物具有降低乳癌和肺癌細胞生長、轉移和肝癌復發率及死亡率之作用。因此本論文將利用細胞實驗探討抗病毒藥物Lamivudine、Ribavirin和Oseltamivir對於肝癌細胞的影響。利用MTT assay、Transwell assay、Scratch wound–healing assay發現經過24、48小時不同濃度處理，Oseltamivir 具有抑制HepG2肝癌細胞生長、存活、移行和侵襲之能力。利用西方墨點法分析發現Oseltamivir可以誘導肝癌細胞表現凋亡相關蛋白。綜合以上結果，我們發現抗病毒藥物Oseltamivir具有抑制人類肝癌細胞的生長侵襲、轉移能力並且能夠促進肝癌細胞死亡。期望這項新發現可以應用於肝癌治療，造福更多肝癌患者。Hepatocellular carcinoma (HCC) is a global health problem and currently the fourth leading cause of cancer mortality in the world. In Taiwan, infected with hepatitis B and hepatitis C is the leading cause of liver cancer, and the current study confirms that hepatitis B carrier with take antiviral medication, could achieved delay the development of liver disease, and prevent or reduce the occurrence of liver cirrhosis, liver failure, and even HCC. It has been suggested that antiviral drugs can reduce the growth, metastasis, recurrence and mortality of breast and lung cancer cells. Therefore, the current study tests the effect of the antiviral drug, Lamivudine, Ribavirin and Oseltamivir, on liver cancer cells. MTT assay, Transwell assay and Scratch wound healing assay showed that Oseltamivir could inhibit the growth, survival, migration and invasion of HepG2 hepatocellular carcinoma cells after 24 and 48 hours treatment. Western blot analysis showed that Oseltamivir induced apoptosis-related proteins in HepG2 cells. In conclusion, these findings indicate that the antiviral drug Oseltamivir can inhibit the growth, invasion and metastasis of human liver cancer cells and promote the death of liver cancer cells. Hoped that this new discovery can be applied to the treatment of liver cancer and benefit more liver cancer patients.癌症肝細胞癌抗病毒藥細胞死亡CancerHepatocellular carcinomaAnti-viral drugCell deaththesis